Stock Analiz

Adlai Nortye Group Ltd. ANL

Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026

$10.61Market cap $683M
Open the interactive analysis →

Adlai Nortye Group Ltd. (ANL) is a healthcare company listed in the US with a market value of about $683M. In the twelve months to June 30, 2026 it had revenue of $18M and net income of -$23M, a net margin of -124.8%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -68%.

About Adlai Nortye Group

Adlai Nortye Group is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2023. Revenue went from $46M in 2021 to $5M in 2025, a decline of about 42.5% a year. It was profitable in 0 of the last 5 years in our data. Its share count fell by 50% over three years (buybacks).

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • Profit margin improving
  • More cash than debt, or low debt to equity
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S37.8
P/B3.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-5.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1154.3%
ROIC (5-yr avg.)-67.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$18M$5M—$5M—$46M
Net income-$23M-$36M-$52M-$109M-$59M-$57M
Free cash flow-$34M-$34M-$52M-$57M-$44M-$4M
EPS (diluted)$-0.66$-0.56$-0.40$-0.85$-0.46$-0.44
Net margin-124.8%-710.6%—-2184.6%—-124.0%
ROIC——-80.7%-54.4%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $29.50, 178% above the current price; targets range from $20.00 to $49.00; the consensus rating is “Strong buy”; expected EPS is $-0.18 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Adlai Nortye Group pay a dividend?

Not currently.

Is Adlai Nortye Group a good stock to buy?

We do not give buy or sell advice. Adlai Nortye Group scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.